Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil

Back to Search
Print
Bookmark Trial

NCT01897740

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Moscow Research Institute of Pediatrics and Pediatric Surgery
Moscow, , 125412, Russian Federation
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
10-30 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients Who Completed study A1481156 and Are Judged by the Investigator to Derive Clinical Benefit from Continued Treatment with Sildenafil, Prior to Reimbursement and Availability for Subjects in Russian Federation.

- Child bearing age women should have appropriate contraception.

- Signed informed consent. Patients who have a wish and possibility to follow treatment regimens in terms of the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pregnant and lactating women.


- Participation in other studies in the current moment or during study period except of
A1481156.


- Patients with severe acute or chronic diseases psychiatric disorders or laboratory
abnormalities.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pulmonary Arterial HypertensionPatient Reported Outcomes in Pulmonary Arterial Hypertension
NCT01792622
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionOpen Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
NCT00878943
  1. Hyderabad, Andra Pradesh
  2. Ahmedabad, Gujarat
  3. Vadodara, Gujarat
  4. Bangalore, Karnataka
  5. Noida, Uttar Pradesh
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionAssess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
NCT00323297
  1. Los Angeles, California
  2. Detroit, Michigan
  3. Pittsburgh, Pennsylvania
  4. Houston, Texas
  5. Houston, Texas
  6. San Antonio, Texas
  7. Darlinghurst, New South Wales
  8. Chermside, Queensland
  9. Praha 2,
  10. Praha 4,
  11. Lille,
  12. Lille,
  13. Vandoeuvre Les Nancy,
  14. Berlin,
  15. Coburg,
  16. Essen,
  17. Giessen,
  18. Hannover,
  19. Homburg,
  20. Leipzig,
  21. Muenchen,
  22. Nuernberg,
  23. Wuerzburg,
  24. Haidari, Athens
  25. Haifa,
  26. Petach Tikva,
  27. Napoli,
  28. Roma,
  29. Taipei,
  30. Papworth Everard, Cambridgeshire
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionTo Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
NCT00430716
  1. Phoenix, Arizona
  2. Augusta, Georgia
  3. Decatur, Georgia
  4. Elk Grove Village, Illinois
  5. Indianapolis, Indiana
  6. Chapel Hill, North Carolina
  7. Charlotte, North Carolina
  8. Charlotte, North Carolina
  9. Houston, Texas
  10. Houston, Texas
  11. Salt Lake City, Utah
  12. Richmond, Virginia
  13. Richmond, Virginia
  14. Richmond, Virginia
  15. Richmond, Virginia
  16. Leuven,
  17. Porto Alegre, RS
  18. Sao Paulo, SP
  19. Sofia,
  20. Sofia,
  21. Beijing,
  22. Shanghai,
  23. Haidari, Athens
  24. Hyderabad, Andhra Pradesh
  25. Ahmedabad, Gujarat
  26. Vadodara, Gujarat
  27. Bangalore, Karnataka
  28. Noida, Uttar Pradesh
  29. Pavia,
  30. Roma,
  31. Riga,
  32. Kuala Lumpur,
  33. Amsterdam,
  34. Rotterdam,
  35. Manila City,
  36. Quezon City,
  37. Krakow,
  38. Zabrze,
  39. Timisoara, Timis
  40. Iasi,
  41. Moscow,
  42. Moscow,
  43. Amphoe Mueang, Khon Kaen
  44. Bangkok,
  45. Norwich, Norfolk
  46. Newcastle Upon Tyne, Tyne and Wear
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
Official Title A LOCAL, SINGLE-CENTRE, EXTENSION, OPEN LABEL ACCESS STUDY, TO PROVIDE SILDENAFIL THERAPY FOR SUBJECTS WHO COMPLETED A1481156 STUDY AND ARE JUDGED BY THE INVESTIGATOR TO DERIVE CLINICAL BENEFIT FROM CONTINUED TREATMENT WITH SILDENAFIL, PRIOR TO REIMBURSEMENT AND AVAILABILITY FOR SUBJECTS IN RUSSIAN FEDERATION
Brief Summary The purpose of this study is to provide Sildenafil therapy for subjects who completed A1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with Sildenafil, prior to reimbursement and availability for subjects in the Russian Federation.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Pulmonary Arterial Hypertension
Intervention Drug: sildenafil
tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ? 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:

  • Patients Who Completed study A1481156 and Are Judged by the Investigator to Derive Clinical Benefit from Continued Treatment with Sildenafil, Prior to Reimbursement and Availability for Subjects in Russian Federation.
  • Child bearing age women should have appropriate contraception.
  • Signed informed consent. Patients who have a wish and possibility to follow treatment regimens in terms of the study.

Exclusion Criteria:

  • Pregnant and lactating women.
  • Participation in other studies in the current moment or during study period except of A1481156.
  • Patients with severe acute or chronic diseases psychiatric disorders or laboratory abnormalities.
Sex/Gender
Sexes Eligible for Study:All
Ages 10 Years to 30 Years   (Child, Adult)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number NCT01897740
Other Study ID Numbers A1481307
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2020